Get the Stockscreener App
0.8452
0.77%
-0.0066
After Hours:
.84
-0.0052
-0.62%
Longeveron Inc stock is traded at $0.8452, with a volume of 417.94K.
It is down -0.77% in the last 24 hours and down -25.20% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$0.8518
Open:
$0.8697
24h Volume:
417.94K
Relative Volume:
0.08
Market Cap:
$24.75M
Revenue:
$1.20M
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.6499
EPS:
-1.3005
Net Cash Flow:
$-19.24M
1W Performance:
-0.68%
1M Performance:
-25.20%
6M Performance:
+14.68%
1Y Performance:
-43.28%
1-Day Range:
$0.8402
$0.8844
1-Week Range:
$0.8402
$0.8984
52-Week Range:
$0.475
$1.80
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.8452 | 24.75M | 1.20M | -22.70M | -19.24M | -1.3005 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN
Longeveron Says the FDA No Longer Sees Trial for Heart Syndrome Treatment as Pivotal - Moomoo
Longeveron Holds Constructive FDA Type C Meeting on ELPIS II Phase 2b Trial for HLHS, Top-Line Results Expected August 2026 - Minichart
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
Longeveron faces setback as FDA no longer views HLHS trial as pivotal - Investing.com UK
Longeveron Updates FDA Path for ELPIS II Trial - TipRanks
FDA shifts stance on Longeveron (LGVN) ELPIS II HLHS trial but keeps future path open - Stock Titan
Rare heart syndrome trial loses pivotal label before August data - Stock Titan
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) - Yahoo Finance
LGVN SEC FilingsLongeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Longeveron (LGVN) is preparing for policy changes | Q4 2025: Profit SurprisesCommunity Risk Signals - newser.com
Earnings Preview: Longeveron to Report Financial Results Post-market on May 13 - Moomoo
Longeveron (LGVN) General Counsel receives 250,000-share RSU equity grant - Stock Titan
Longeveron (NASDAQ: LGVN) CEO receives 500,000 RSUs grant - Stock Titan
Longeveron (LGVN) CTO Devin Blass receives 250,000 RSU share award - Stock Titan
Longeveron (NASDAQ: LGVN) grants CMO 250,000 time-based RSUs - Stock Titan
Longeveron (LGVN) CFO awarded 250,000 RSUs of Class A stock - Stock Titan
Longeveron (LGVN) proxy seeks share increase, 1:2–1:20 reverse split - Stock Titan
Longeveron plans May 13 business update after market close - Stock Titan
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 - Yahoo Finance
H.C. Wainwright Maintains Longeveron(LGVN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Longeveron to report Q1 2026 financial results and host conference call on May 13 - Pluang
H.C. Wainwright cuts Longeveron stock price target on dilution By Investing.com - Investing.com Australia
H.C. Wainwright cuts Longeveron stock price target on dilution - Investing.com
LGVN Q1'26 Earnings: revenue estimate is 374.00K USD - TradingView
LGVN Stock Price, Quote & Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
Longeveron appoints interim CEO - MSN
The Longevity Trade Is No Longer a Buzzword — It's a $120 - GlobeNewswire
Longeveron | EFFECT: Others - Moomoo
Longeveron (LGVN) Stock Good Till Cancel (Bearish Sentiment) 2026-04-20Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
[EFFECT] Longeveron Inc. SEC Filing - Stock Titan
30.9M Longeveron shares registered for resale (NASDAQ: LGVN) - Stock Titan
Longeveron (LGVN) Stock Comparable Valuation (Selling Pressure) 2026-04-16Quantitative Analysis - newser.com
Longeveron Restores Executive Pay After Recent Financing - TipRanks
What is the long-term potential of Longeveron (LGVN) Stock | LGVN Q4 Earnings: Beats Estimates by $0.19Core Business Growth - Xã Thanh Hà
Longeveron Inc. Files Form 8-K Current Report with SEC – Company Details and Stock Information (2026) - Minichart
Aug Setups: Is Longeveron Inc stock a value trapMarket Growth Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Longeveron restores executive pay, approves new stock unit grants following financing By Investing.com - Investing.com South Africa
Longeveron restores executive pay, approves new stock unit grants following financing - Investing.com
Longeveron IncRepaid Executives For Compensation Reductions Following FinancingSEC Filing - TradingView
Longeveron grants RSUs to executives after restoring reduced pay - TradingView — Track All Markets
Longeveron (NASDAQ: LGVN) restores pay and grants RSUs after financing - Stock Titan
Longeveron Prospectus Filed For Resale Of Up To 30.9 Million Class A Common Shares By Selling Stockholders- SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) resale filing details 30.9M registered shares - Stock Titan
Biotechs Racing to Translate Longevity Science Into Real Therapies — And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Cantech Letter
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Finansavisen
IPO Launch: What is Longeveron Incs book value per share2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Longeveron receives China patent for stem cell potency assay By Investing.com - Investing.com Canada
Longeveron receives China patent for stem cell potency assay - Investing.com
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):